Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 4/20 | 0.62 |
| ▸ | CLK1 | P49759 | 3/20 | 0.62 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.62 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.62 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.62 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.62 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.62 |
| ▸ | MTOR | P42345 | 2/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.62 |
| ▸ | CLK2 | P49760 | 2/20 | 0.62 |
| ▸ | GAK | O14976 | 1/20 | 0.62 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.62 |
| ▸ | STK10 | O94804 | 1/20 | 0.62 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.62 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.62 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.62 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.62 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.62 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.62 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4397976 | 1.00 | PIM1 (0.62) | PIM1CLK1DYRK1APIK3CDCSNK2A2 | |
| SCHEMBL1497364 | 0.90 | HIPK2 (0.67) | PIM1CLK1DYRK1APIK3CDCSNK2A2 | |
| SCHEMBL2400383 | 0.90 | HIPK2 (0.67) | PIM1CLK1DYRK1APIK3CDCSNK2A2 | |
| SCHEMBL2400377 | 0.90 | HIPK2 (0.67) | PIM1CLK1DYRK1APIK3CDCSNK2A2 | |
| SCHEMBL4397967 | 0.89 | PIK3CD (0.62) | PIM1CLK1DYRK1APIK3CDCSNK2A2 | |
| SCHEMBL4397965 | 0.89 | PIK3CD (0.62) | PIM1CLK1DYRK1APIK3CDCSNK2A2 | |
| SCHEMBL1497385 | 0.88 | PIK3CG (0.58) | PIM1CLK1DYRK1APIK3CDCSNK2A2 | |
| SCHEMBL2395721 | 0.88 | PIK3CG (0.58) | PIM1CLK1DYRK1APIK3CDCSNK2A2 | |
| SCHEMBL2395716 | 0.88 | PIK3CG (0.58) | PIM1CLK1DYRK1APIK3CDCSNK2A2 | |
| SCHEMBL2395285 | 0.84 | PIK3CD (0.52) | PIM1CLK1DYRK1APIK3CDCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306074-A1 | THIAZOLIDINEDIONE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-12-10 | — | — | US | claimed |
| US-20080255115-A1 | THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | DARCY MICHAEL GERARD | 2008-10-16 | — | — | US | claimed |
| US-20090306074-A1 | THIAZOLIDINEDIONE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-12-10 | — | — | US | disclosed |
| US-20090306074-A1 | THIAZOLIDINEDIONE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-12-10 | — | — | US | disclosed |
| US-20090306074-A1 | THIAZOLIDINEDIONE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-12-10 | — | — | US | disclosed |
| US-20080255115-A1 | THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | DARCY MICHAEL GERARD | 2008-10-16 | — | — | US | disclosed |
| US-20080255115-A1 | THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | DARCY MICHAEL GERARD | 2008-10-16 | — | — | US | disclosed |
| US-20080255115-A1 | THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | DARCY MICHAEL GERARD | 2008-10-16 | — | — | US | disclosed |
| WO-2007136940-A2 | THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255115-A1 | THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | PI4KA, JAK3, PIK3CD | PIM1 280/4885CLK1 2880/4885DYRK1A 2423/4885 |
| US-20090306074-A1 | THIAZOLIDINEDIONE DERIVATIVES AS P13 KINASE INHIBITORS | JAK3, DPP3, ADRB3 | PIM1 717/4885CLK1 2709/4885DYRK1A 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.